Financial resources allocated to the use of PD1/PD-L1 inhibitors in lower-income countries must be carefully assessed for cost-effectiveness and weighed against the opportunity costs arising from the potential benefits lost from alternative uses (e.g., an estimated additional US$20 billion per year required to implement an essential package of cancer control interventions34). This evidence concerns the gene CD274 and cancer.